RAB34

Across TCGA pan-cancer cohorts, RAB34 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAB34 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB34 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB34 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and HNSC are the cancer types where RAB34 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.217	0.490	<.001	41	view →
CCRCC	DFS	Median	All	0.448	1.000	<.001	38	view →
HNSC	DFS	Median	All	0.540	0.735	.014	13	view →
LUAD	DFS	Tertile	II,III,IV	0.215	0.871	.012	11	view →
UCEC	DFS	Tertile	All	0.816	1.000	.005	8	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAB34–PDAC (DFS)

Open the PDAC breakdown →